Do Japanese and Swedish peptic ulcer patients respond differently to Helicobacter pylori eradication therapies and what are their histological features?

Scandinavian Journal of Gastroenterology

Volumn 38, Issue 5, 2003, Pages 482-490

  Unge, Peter ^a   Kimura, K ^b   Sipponen, P ^b   Ekstrom P ^b   Satoh, K ^b   Hellblom, M ^b   Ohlin, B ^b   Stubberod A ^b   Kihira, K ^b   Yube, T ^b   Yoshida, Y ^b  

^a Bollnas Hospital   (Sweden)

^b NONE

Author keywords

Duodenal ulcer; Eradication; Ethnic groups; Gastric atrophy; Gastric ulcer; Helicobacter pylori; Treatment

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; EPIGASTRIC PAIN; ETHNIC DIFFERENCE; FEMALE; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; JAPAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SIDE EFFECT; SORE THROAT; STOMACH DISEASE; STOMACH ULCER; STOMATITIS; SWEDEN; UREA BREATH TEST;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER; SWEDEN;

EID: 0038137602     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310000951     Document Type: Article

References (22)

1. NIH Consensus Conference., Helicobacter pylori in peptic ulcer disease NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
2. Unge P, Gad A, Eriksson K, Bergman B, Carling L, Ekström P, et al. Amoxicillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients. Eur J Gastroenterol Hepatol 1993;5:325-31.
3. Malfertheiner P, O'Morain C, Michetti P. The Maastricht Guidelines and other innovations. Curr Opin Gastroenterol 1997;13 Suppl 1:1-7.
4. Malfertheiner P, Bayerdörffer E, Diete U, Gil J, Lind T, Misiuna P, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999;13:703-12.
5. Axon ATR, O'Moráin CA, Bardhan KD, Crowe JP, Beattie AD, Thompson RPH, et al. Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. Br Med J 1997;314:565-86.
6. IARC monographs on the valuation of carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori. Monograph 61, Lyon, France: International Agency for Research on Cancer 1994.
7. Sipponen P. Helicobacter pylori and gastric premalignant conditions. Acta Gastro-Enterologica Belgica 1991;54:340-4.
8. Zanten SJ, Bradette M, Farley A, Leddin D, Lind T, Unge P, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing inpatients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999;13:289-95.
9. Malfertheiner P, Mégraud F, O'Morain CO, Hungin APS, Jones R, Axon A, et al, The European Helicobacter pylori Study Group (EHPSG)., Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000. Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
10. Imai T, Kubo T, Watanabe H. Chronic gastritis in Japanese with reference to the high incidence of gastric carcinoma. J Nat Cancer Inst 1971;47:179-95.
11. Parkin DM. Epidemiology of cancer: global patterns and trends. Toxicol Lett 1998;102-3:227-34.
12. 13C-urea breath test. In: Rathbone BJ, Heatley RV, editors. Helicobacter pylori and gastroduodenal disease, 2nd edn. Oxford: Blackwell Scientific; 1992. p. 88-106.
13. Price AB. The 'Sydney System': Histological division. J Gastroenterol Hepatol 1991:6:209-22.
14. Mégraud F. Epidemiology of Helicobacter pylori infection. Gastroenterol Clinic N Am 1993;22:73-88.
15. Logan RP, Bardhan KD, Celestin LR, Theodossi A, Palmer KR, Reed PI, et al. Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomised, double-blind, multi-centre trial of omeprazole with or without clarithromycin. Aliment Pharmacol Ther 1995;9:417-23.
16. Gerber MA. Antibiotic resistance: relationship to persistence of group A streptococci in the upper respiratory tract. Pediatrics 1996;97:971-5.
17. Katsukawa C, Harada K, Nakasone C. Epidemiological survey of group A haemolytic streptococci isolated in Osaka during the 21-year period between 1967 and 1987. Part II. J Jap Ass Inf Dis 2989;63:1265-9.
18. Mégraud F, Lehn N, Lind T, Bayerdörffer E, O'Morain C, Spiller R, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999;43:2747-52.
19. Glupczynski Y. Antimicrobial resistance in Helicobacter pylori: a global overview. Acta Gastroenterol Belg 1998;61:357-66.
20. Iovene MR, Romano M, Pilloni AP, Giordano B, Montella F, Caliendo S, et al. Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori. Chemotherapy 1999;45:8-14.
21. Aro P, Ronkainen J, Storskrubb T, Bolling-Sternevald E, Talley NJ, Agreus L. Prevalence of symptoms and upper endoscopic findings in a random adult population. The Kalixanda Study. Gastroenterology 2001;120:A1209.
22. Lain SK. Epidemiology and genetics of peptic ulcer. Gastroenterol Japan 1993;28:147-57.